Mycobacterium tuberculosis (M. tb), the causative agent of TB, is a recalcitrant pathogen that
is rife around the world, latently infecting approximately a quarter of the worldwide …

The need for new antibacterial drugs to treat the increasing global prevalence of drug-
resistant bacterial infections has clearly attracted global attention, with a range of existing …

Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …

The development of new and effective antibacterial drugs to treat multi-drug resistant (MDR)
bacteria, especially Gram-negative (G− ve) pathogens, is acknowledged as one of the …

Background Tuberculosis is the world's leading infectious disease killer. We aimed to
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …

Tuberculosis (TB) is a serious public health problem worldwide. Its situation is worsened by
the presence of multidrug resistant (MDR) strains of Mycobacterium tuberculosis, the …

Highlights•Incidence of lung disease caused by non-TB mycobacteria (NTM) is
increasing.•Current treatments are ineffective.•There is an urgent need to establish a drug …

Despite intensive efforts to discover highly effective treatments to eradicate tuberculosis
(TB), it remains as a major threat to global human health. For this reason, new TB drugs …

Natural product drug discovery has regained interest due to low production costs, structural
diversity, and multiple uses of active compounds to treat various diseases. Attention has …

The causative agent of tuberculosis (TB), Mycobacterium tuberculosis and more recently
totally drug‐resistant strains of M. tuberculosis, display unique mechanisms to survive in the …